FDA approves Intramuscular (IM) administration as an option for M-M-R II (measles-mumps-rubella vaccine), VARIVAX (varicella vaccine), and ProQuad (measles-mumps-rubella- varicella vaccine) from Merck
Oakland County, Michigan sent this bulletin at 03/17/2023 05:02 PM EDTThis email is being sent to VFC, Non-VFC and Covid-19 Providers in Oakland County, Michigan by the Oakland County Health Division (OCHD) Immunization Action Plan (IAP)
Dear Immunization Partners,
Please share the following information with colleagues and staff in your practice.
On March 6th, 2023, Merck announced that the U.S. Food and Drug Administration (FDA) approved the addition of the intramuscular (IM) route of administration to the United States Product Insert (USPI) for Merck’s MMRV (measles-mumps-rubella-varicella) family of vaccines: M-M-R®II (measles-mumps-rubella vaccine), VARIVAX® (varicella vaccine), and ProQuad®(measles-mumps-rubella-varicella vaccine). Previously, these vaccines were only licensed for subcutaneous administration. They are now approved for either IM or subcutaneous administration.
Two brands of MMR vaccine are distributed in the United States. Only Merck’s brand is licensed for either IM or subcutaneous administration. Priorix from GSK is licensed for subcutaneous administration only.
See the following resources for more information:
Package Insert - M-M-R II (fda.gov)
Package Insert - PROQUAD (fda.gov)
Package Insert - VARIVAX (fda.gov)
Thank you,
Oakland County Health Division, Immunization Action Plan
Any questions should be directed to Letha Martin, preferably by email at martinl@oakgov.com
 |
Questions? Contact Us |
| STAY CONNECTED: | |||||
 |
 |
 |
 |
||
SUBSCRIBER SERVICES:
Manage Preferences | Unsubscribe | Help
This service is provided to you by Oakland County, Michigan.